A Comprehensive Pharmacological and Clinical Review of LY2140023 (Pomaglumetad Methionil): A Pioneering Glutamatergic Agent for Schizophrenia

Introduction: The Unmet Need in Schizophrenia and the Dawn of the Glutamate Hypothesis

The Limitations of the Dopamine Hypothesis

For over six decades, the development of antipsychotic pharmacotherapies has been overwhelmingly guided by the dopamine hypothesis of schizophrenia.[1] This paradigm, born from the observation that all effective antipsychotic drugs exhibit antagonist activity at the dopamine D2 receptor, has led to the creation of numerous first- and second-generation agents.[3] While these medications can be effective in mitigating the positive symptoms of the disorder, such as hallucinations and delusions, they leave a profound therapeutic void.[3] The negative symptoms (e.g., apathy, anhedonia, social withdrawal) and the pervasive cognitive deficits that are core features of schizophrenia remain largely refractory to treatment with dopamine-blocking agents.[3] Furthermore, the clinical utility of these drugs is often compromised by a burdensome side-effect profile, including debilitating extrapyramidal symptoms (EPS), metabolic dysregulation leading to significant weight gain and diabetes, and hyperprolactinemia.[3] This reality underscores a critical unmet medical need and points to the limitations of a purely dopaminergic model of schizophrenia pathophysiology.

Emergence of the Glutamate Hypothesis

In the search for alternative therapeutic targets, the glutamate hypothesis of schizophrenia emerged as a compelling and more comprehensive framework.[1] This hypothesis is strongly supported by pharmacological evidence demonstrating that antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor, such as phencyclidine (PCP) and ketamine, can induce a state in healthy individuals that closely mimics the full spectrum of schizophrenia symptoms—positive, negative, and cognitive.[5] This observation suggested that hypofunction of the NMDA receptor and a subsequent dysregulation of the brain's primary excitatory neurotransmitter system may be central to the pathophysiology of the illness.[7] This paradigm shift opened new avenues for drug development, moving the focus from blocking dopamine to modulating glutamate in brain circuits believed to be hyperactive in schizophrenia.[9]

LY2140023: A Pioneer in Glutamatergic Modulation

Within this new scientific landscape, LY2140023 (pomaglumetad methionil) was developed by Eli Lilly and Company as a first-in-class investigational agent. It represented a rational, "bench to bedside" attempt to translate the glutamate hypothesis into a viable clinical therapy.[3] LY2140023 was designed as a novel, non-dopaminergic antipsychotic with a mechanism of action aimed at restoring balance to the dysregulated glutamate system.[8] The development of this compound was not merely an incremental advance but a potential paradigm shift. It represented a high-risk, high-reward strategy to move beyond the well-established path of D2 antagonists and address what was believed to be a more fundamental aspect of schizophrenia's pathophysiology. The success or failure of LY2140023 was therefore poised to have profound implications for the entire field, serving as a critical test of the viability of targeting metabotropic glutamate receptors and influencing future investment in non-dopaminergic approaches to treating psychosis.

Physicochemical Profile and Prodrug Formulation

A precise understanding of the chemical identity and formulation of LY2140023 is essential for interpreting its pharmacological and clinical data. The compound was developed in several forms, with the prodrug strategy being central to its viability as an oral therapeutic.

Identification and Nomenclature

LY2140023 is the laboratory designation for pomaglumetad methionil, a methionine amide prodrug.[3] It has been studied and is commercially available for research purposes in several forms:

• Pomaglumetad methionil (anhydrous): The base prodrug, identified by CAS Number 635318-55-7, with a molecular formula of C12​H18​N2​O7​S2​ and a molecular weight of 366.41 g/mol.[14]
• Pomaglumetad methionil monohydrate: This hydrated form, often specified in clinical trial literature as "LY2140023 monohydrate," has the CAS Number 956385-05-0, a molecular formula of C12​H20​N2​O8​S2​, and a molecular weight of 384.4 g/mol.[8] Its IUPAC name is (1R,4S,5S,6S)-4-amino]-2,2-dioxo-2λ6-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid;hydrate.[18]
• Pomaglumetad methionil hydrochloride: A salt form with CAS Number 635318-26-2, molecular formula C12​H19​ClN2​O7​S2​, and a molecular weight of 402.87 g/mol.[19]

The Active Moiety: Pomaglumetad (LY-404039)

It is critical to distinguish the inactive prodrug, LY2140023, from its pharmacologically active metabolite. Upon administration and absorption, LY2140023 is hydrolyzed to yield pomaglumetad (also known as LY-404039).[13] Pomaglumetad is a rigid glutamate analog that functions as a selective and potent agonist at group II metabotropic glutamate receptors (mGluR2/3).[3]

The Rationale for a Prodrug Strategy

The development of LY2140023 as a prodrug was not an incidental choice but a deliberate and necessary feat of pharmaceutical chemistry. The active moiety, pomaglumetad, while possessing a desirable pharmacological profile, suffered from a critical pharmacokinetic flaw: very low oral absorption and bioavailability, which precluded its development as an effective oral medication.[16]

To overcome this barrier, researchers engineered a solution by coupling pomaglumetad with the amino acid L-methionine.[22] This created the prodrug LY2140023, which was specifically designed to be a high-affinity substrate for the human peptide transporter 1 (PEPT1), an active transport protein located in the intestine.[20] This elegant strategy effectively hijacks the body's natural peptide absorption pathways to shuttle the drug into systemic circulation.[22]

Once absorbed, LY2140023 is rapidly and efficiently hydrolyzed, with approximately 70% conversion to the active pomaglumetad.[22] This process dramatically increased the estimated oral bioavailability to a clinically viable 49%.[22] The prodrug itself is pharmacologically inert at the target receptors, with binding affinity (

Ki​) values greater than 100 µM.[22] This successful formulation demonstrates a key principle in drug development: the ultimate failure of the LY2140023 program was not one of chemistry or pharmacokinetics, but one of clinical efficacy. The pharmaceutical science objectives were fully met, allowing a promising but poorly absorbed compound to be rigorously tested in humans.

Table 1: Physicochemical and Pharmacological Identifiers

Compound Name	Form	DrugBank ID	CAS No.	Molecular Formula	MW (g/mol)	Target	Ki​ h-mGluR2 (nM)	Ki​ h-mGluR3 (nM)
LY2140023	Anhydrous Prodrug	DB05096	635318-55-7	C12​H18​N2​O7​S2​	366.41	Inactive	>100,000	>100,000
LY2140023 monohydrate	Monohydrate Prodrug	DB05096	956385-05-0	C12​H20​N2​O8​S2​	384.4	Inactive	>100,000	>100,000
Pomaglumetad (LY-404039)	Active Moiety	-	-	C7​H9​NO6​S	235.21	mGluR2/3	149	92

Data compiled from sources.[14]

Mechanism of Action: Modulating Glutamate via mGluR2/3 Agonism

The Target: Group II Metabotropic Glutamate Receptors (mGluR2 & mGluR3)

The molecular targets of pomaglumetad, the active form of LY2140023, are the metabotropic glutamate receptors 2 and 3 (mGluR2 and mGluR3).[11] These are Class C G-protein coupled receptors (GPCRs) that belong to Group II of the mGluR family. Upon activation by an agonist, they couple to inhibitory Gi/Go proteins, which in turn inhibit the enzyme adenylyl cyclase, leading to a reduction in intracellular levels of the second messenger cyclic adenosine monophosphate (cAMP).[11]

A crucial feature of these receptors is their neuroanatomical localization. They are densely expressed as presynaptic autoreceptors on glutamatergic neurons in brain regions strongly implicated in the pathophysiology of schizophrenia, including the prefrontal cortex, striatum, hippocampus, and thalamus.[3] When activated, these autoreceptors initiate a negative feedback loop that inhibits further release of glutamate from the presynaptic terminal.[16] Experiments in knockout mice have suggested that the activation of mGluR2, in particular, is associated with the antipsychotic-like behavioral effects of these agonists.[3]

Pharmacodynamics of Pomaglumetad (LY-404039)

Pomaglumetad acts as a potent and highly selective full agonist at both mGluR2 and mGluR3.[22] It binds with high affinity to the human recombinant receptors, with a reported

Ki​ of 149 nM for mGluR2 and 92 nM for mGluR3.[15] This selectivity is a key feature; the compound demonstrates negligible affinity for other glutamate receptor subtypes (e.g., NMDA, AMPA, kainate) and, importantly, does not interact with the monoaminergic receptors (dopamine, serotonin, adrenergic) that are the primary targets of existing antipsychotic drugs.[3]

Its functional activity as an agonist has been confirmed in vitro and ex vivo. Pomaglumetad effectively inhibits forskolin-stimulated cAMP formation, consistent with its action via Gi/Go proteins.[22] Furthermore, it potently suppresses electrically stimulated excitatory postsynaptic potentials (EPSPs) in striatal neurons in a concentration-dependent manner. This effect is a direct consequence of reduced presynaptic glutamate release and is reversed by the application of a selective mGluR2/3 antagonist, confirming the on-target mechanism of action.[22]

The Therapeutic Hypothesis: Normalizing Glutamatergic Hyperactivity

The central therapeutic hypothesis for LY2140023 was predicated on the idea that schizophrenia involves a state of cortical glutamate hyperactivity, possibly as a downstream consequence of NMDA receptor hypofunction.[8] By acting as an agonist at presynaptic mGluR2/3 autoreceptors, pomaglumetad was expected to function as a "glutamatergic brake," reducing excessive glutamate release and thereby normalizing the activity of dysregulated cortical pyramidal neurons.[9]

This mechanism represents a fundamentally different and more nuanced therapeutic strategy than that of standard antipsychotics. Rather than directly blocking postsynaptic receptors in an antagonistic fashion, pomaglumetad was designed to be modulatory and restorative. It aimed to reinstate homeostatic balance within the glutamate system by engaging its natural negative feedback machinery. This elegant mechanism held the theoretical promise of achieving antipsychotic efficacy while avoiding the significant off-target effects and compensatory receptor changes associated with chronic dopamine receptor blockade.

Downstream Effects on Monoamines

While its primary action is on the glutamate system, preclinical evidence indicated that pomaglumetad also produces downstream effects on monoamine neurotransmitter systems. In rat studies, oral administration of LY2140023 led to a dose-dependent increase in the cerebrospinal fluid levels of the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA).[14] This profile of increased prefrontal dopamine turnover is notably similar to that of the highly effective atypical antipsychotic clozapine.[22] The drug was also shown to increase serotonin turnover.[22] These findings suggest a complex interplay between the glutamate and monoamine systems, whereby modulating the primary excitatory system can indirectly influence the neurotransmitter pathways targeted by conventional antipsychotics.

The Clinical Development Journey of Pomaglumetad Methionil

The clinical development of pomaglumetad methionil was a turbulent journey, characterized by a highly promising early signal that was ultimately not replicated in large-scale, definitive trials.

Phase I: Foundational Safety and Pharmacology

The Phase I program established the initial safety, tolerability, and pharmacokinetic profile of LY2140023. Studies were conducted in healthy volunteers to determine appropriate dosing and confirm the prodrug's conversion to its active moiety.[24] A dedicated study in patients with schizophrenia (NCT01606436) was performed to specifically evaluate the drug's effect on cardiac conduction (QTc interval), a critical safety assessment for CNS drugs, which did not reveal significant concerns.[25] The program also included small, exploratory Phase I studies for other potential indications, such as a trial for individuals at clinical high risk for psychosis (NCT03321617) and a trial in post-traumatic stress disorder (NCT02234687), which was ultimately terminated.[26]

Phase II: From Proof-of-Concept to Inconclusive Results

The Phase II program yielded contradictory results that became a central feature of the drug's story.

• The "Proof-of-Concept" Success (Study HBBD): The development program was galvanized by an initial Phase II study, the results of which were published in the high-impact journal Nature Medicine.[28] In this randomized, placebo- and active-controlled trial, patients treated with LY2140023 (40 mg twice daily, or BID) demonstrated a statistically significant improvement in total scores on the Positive and Negative Syndrome Scale (PANSS) compared to placebo. The magnitude of this effect was comparable to that of the active control, olanzapine.[28] This was a landmark finding, providing the first clinical evidence that an mGluR2/3 agonist possessed antipsychotic activity in humans.[28] The drug was also well-tolerated, with a notable absence of weight gain, EPS, and prolactin elevation.[3]
• The Inconclusive Follow-up (Study HBBI): A subsequent, larger, multi-dose Phase II study (HBBI) failed to replicate these promising findings, yielding inconclusive results.[12] In a critical blow, neither any of the four doses of LY2140023 nor the active comparator olanzapine demonstrated a statistically significant separation from placebo on the primary PANSS endpoint.[29] Eli Lilly attributed this failure to an anomalously high placebo response, which was observed to be approximately double the rate seen in historical schizophrenia trials.[30] This study also raised the first significant safety concern, with convulsions being reported in a small number of patients receiving LY2140023.[29]

The progression from a spectacular success in one trial to a complete failure to show a signal in the next illustrates the challenge of reproducibility in clinical science. The decision to attribute the HBBI failure to an external factor (the placebo response) rather than a potential issue with the drug itself, and to proceed to Phase III based on the strength of the initial HBBD study, proved to be a pivotal and ultimately fateful choice.

Phase III: The Pivotal Trials and Program Termination

Despite the ambiguity of the Phase II data, the company advanced pomaglumetad methionil into a large and costly Phase III program.

• Pivotal Monotherapy Trials (HBBM & HBBN): Study HBBM (NCT01086748) was a large-scale (N=1013), multicenter, randomized, placebo-controlled registration trial.[32] The results were definitive and negative. Neither the 40 mg BID nor the 80 mg BID dose of LY2140023 met the primary endpoint of demonstrating a significant improvement over placebo on the PANSS total score.[32] Crucially, the active control, risperidone, did show a robust and statistically significant separation from placebo, confirming the trial's assay sensitivity and isolating the failure to LY2140023 itself.[32] In light of these results, an independent futility analysis was conducted on the second ongoing pivotal study (HBBN), which concluded that it was also highly unlikely to succeed. This led Eli Lilly to terminate the entire monotherapy development program in 2012.[34]
• Adjunctive and Long-Term Studies: The program included other key late-stage trials. A Phase II study (HBCO) evaluating LY2140023 as an adjunctive therapy for patients with prominent negative symptoms also failed to meet its primary endpoint.[33] A 24-week, double-blind Phase 3 study (NCT01328093) directly compared LY2140023 to aripiprazole, with a primary focus on long-term safety and weight gain.[38] Finally, a dedicated Phase 3 withdrawal study (NCT01452919) found no evidence of physical dependence upon abrupt discontinuation of the drug.[40]

Table 2: Summary of Major Clinical Trials for Pomaglumetad Methionil in Schizophrenia

Trial ID	Phase	Design	N	Population	Interventions	Primary Endpoint	Outcome
HBBD	II	R, DB, PC, AC	196	Acute Exacerbation	LY2140023 40mg BID, Olanzapine 15mg QD, Placebo	Change in PANSS Total Score	Positive
HBBI	II	R, DB, PC, AC	669	Acute Exacerbation	LY2140023 (4 doses), Olanzapine 15mg QD, Placebo	Change in PANSS Total Score	Inconclusive
HBBM (NCT01086748)	II/III	R, DB, PC, AC	1013	Acute Exacerbation	LY2140023 40/80mg BID, Risperidone 2mg BID, Placebo	Change in PANSS Total Score	Negative/Failed
HBCO	II	R, DB, PC	-	Prominent Negative Symptoms (Adjunctive)	LY2140023 20mg BID, Placebo (added to SGA)	Change in NSA-16 Total Score	Negative/Failed
NCT01328093	III	R, DB, AC	678	Schizophrenia	LY2140023 (flex dose), Aripiprazole (flex dose)	Weight Gain Comparison	Met primary; inferior efficacy
NCT01452919	III	R, DB, PC (Withdrawal)	-	Schizophrenia	LY2140023 vs. Placebo (after open-label phase)	Physical Dependence Assessment	No dependence observed

R=Randomized, DB=Double-Blind, PC=Placebo-Controlled, AC=Active-Controlled, SGA=Second-Generation Antipsychotic. Data compiled from sources.[12]

A Critical Assessment of Clinical Efficacy

A systematic review of the clinical trial data reveals a consistent pattern of efficacy failure in the late-stage development of pomaglumetad methionil, marking a clear disconnect between the preclinical hypothesis and the clinical reality for a broad patient population.

Primary Efficacy Endpoint Failure

The definitive conclusion from the pivotal registration program was the drug's inability to demonstrate a therapeutic effect superior to placebo. In the large-scale HBBM trial, the primary analysis of change from baseline in PANSS total score showed no significant difference between either dose of LY2140023 and placebo.[32] The one-sided p-values were reported as 0.154 for the 40 mg BID dose and 0.698 for the 80 mg BID dose, falling far short of the threshold for statistical significance.[32] This failure to separate from placebo was the primary and unequivocal reason for the termination of the program.[33]

Inferiority to Standard of Care

In trials that included an active comparator, LY2140023 was shown to be not only ineffective against placebo but also significantly less effective than existing standard-of-care (SOC) antipsychotics.

• In the 24-week, double-blind Phase 3 comparison study (NCT01328093), the mean improvement in PANSS total score was significantly greater for patients treated with aripiprazole (-15.58) than for those treated with pomaglumetad methionil (-12.03), with a p-value of 0.045.[12]
• Similarly, in the 24-week open-label study HBBR, while initial improvement was similar between groups, the SOC group demonstrated significantly greater improvement in PANSS total score at the final 24-week endpoint (p=0.004).[31]

Lack of Efficacy on Negative Symptoms

A key hope for glutamatergic agents was their potential to address the negative symptoms of schizophrenia, a major limitation of dopaminergic drugs. However, the clinical data did not support this hypothesis for LY2140023. In the HBCO study, which specifically enrolled patients with prominent negative symptoms, the addition of LY2140023 to an existing second-generation antipsychotic provided no significant benefit over the addition of placebo. The change from baseline on the 16-item Negative Symptom Assessment (NSA-16) total score was not significantly different between the treatment groups at any point during the study (all p>0.131).[37]

Higher Discontinuation Due to Lack of Efficacy

The poor efficacy observed by clinicians was mirrored in patient outcomes. In the long-term open-label HBBR study, a significantly greater proportion of patients randomized to the LY2140023 group discontinued the trial due to a lack of efficacy when compared to the SOC group (20.8% vs. 11.5%; p=0.044).[29] This indicates that from both a clinical and patient perspective, the drug was not providing adequate symptom control.

The Differentiated Safety and Tolerability Profile

While the efficacy results were disappointing, the clinical program for LY2140023 did successfully demonstrate a safety and tolerability profile that was distinct from dopamine D2 receptor antagonists, confirming a key aspect of its mechanistic hypothesis.

The Key Advantage: Absence of Dopaminergic Side Effects

The most consistent and positive finding across all trials was the drug's favorable profile regarding the hallmark side effects of conventional antipsychotics.

• Weight Gain and Metabolic Effects: LY2140023 was consistently shown to be weight-neutral or to induce weight loss. This was most clearly demonstrated in the 24-week, head-to-head Phase 3 trial against aripiprazole. At the study's conclusion, the pomaglumetad methionil group had experienced a mean weight loss of 2.8 kg, whereas the aripiprazole group had a mean weight gain of 0.4 kg. This difference was highly statistically significant (p<0.001).[4]
• Extrapyramidal Symptoms (EPS): As predicted by its non-dopaminergic mechanism, LY2140023 was not associated with treatment-emergent motor side effects. In comparative studies, the incidence of parkinsonism (p=0.011) and akathisia (p=0.029) was significantly higher in the SOC groups.[29] This lack of EPS was a robust finding throughout the development program.[3]
• Prolactin Elevation: The drug was not associated with elevations in serum prolactin, avoiding the endocrine and sexual side effects commonly seen with many standard antipsychotics.[28]

Treatment-Emergent Adverse Events (TEAEs)

Despite these advantages, LY2140023 was not without its own tolerability issues.

• Common Adverse Events: The most frequently reported TEAEs associated with the drug were gastrointestinal in nature, including nausea, vomiting, and dyspepsia, as well as CNS effects like headache, insomnia, and agitation.[16] In several studies, vomiting was reported significantly more often in the LY2140023 group compared to both SOC and placebo.[37]
• Serious Adverse Events (SAEs) and Seizure Risk: A more significant safety concern arose during the program. The Phase II HBBI study reported convulsions in four patients treated with LY2140023, identifying a potential increased risk of seizures.[29] Although no seizures were reported in the subsequent pivotal HBBM trial [32], data from the long-term Phase 3 study against aripiprazole revealed a concerning trend. The incidence of SAEs (8.2% vs. 3.1%; p=0.032) and the rate of discontinuation due to adverse events (16.2% vs. 8.7%; p=0.020) were both significantly higher for pomaglumetad methionil compared to aripiprazole.[4]

This presents a critical trade-off. While LY2140023 successfully avoided the metabolic and motor side effects of D2 antagonists, it introduced a different set of tolerability issues that led to more patients discontinuing treatment than with a modern standard-of-care agent. The drug was "better tolerated" on some key metrics but "less tolerable" overall, failing to establish a favorable risk/benefit profile.

Table 3: Comparative Efficacy and Key Safety Outcomes from Pivotal Trials

Outcome Measure	Trial NCT01328093 (vs. Aripiprazole)	Trial HBBM (vs. Placebo/Risperidone)
Treatment Arms	Pomaglumetad (n=516) vs. Aripiprazole (n=162)	Pomaglumetad 40mg (n=289), 80mg (n=291) vs. Placebo (n=290)
Primary Efficacy Outcome
Mean Change in PANSS Total	-12.03	-15.58 (p=0.045)
Key Safety & Tolerability Outcomes
Mean Weight Change (kg)	-2.8	+0.4 (p<0.001)
Incidence of SAEs (%)	8.2%	3.1% (p=0.032)
Discontinuation due to AEs (%)	16.2%	8.7% (p=0.020)

Data compiled from sources.[12]

The Discontinuation of a Promising Candidate: Analysis of Failure

The Official Rationale

The termination of the pomaglumetad methionil development program was a direct result of the unambiguous failure to meet pre-specified efficacy endpoints in pivotal trials. On July 11, 2012, Eli Lilly announced the negative top-line results from the HBBM study, confirming that the drug had not separated from placebo.[33] This was followed by an announcement on August 29, 2012, that the company was halting all ongoing studies, including the second pivotal trial, HBBN.[35] This final decision was prompted by an independent futility analysis which concluded that HBBN was highly unlikely to achieve a positive outcome.[35] The company was clear that the discontinuation was driven by a lack of efficacy, not by safety concerns.[35] The concurrent failure of the adjunctive therapy study (HBCO) further solidified this decision.[34]

This sequence of events represents the proper functioning of the clinical trial process. The pivotal trial program was well-designed, including both a placebo control to establish efficacy and an active comparator (risperidone) to establish assay sensitivity. The fact that risperidone worked while pomaglumetad did not provided a clear, interpretable, and definitive result, preventing an ineffective drug from proceeding further and ultimately protecting patients.

Confounding Factors and Challenges

While the ultimate failure was one of efficacy, the drug's development was complicated by factors inherent to psychiatric clinical research.

• The Placebo Effect: The exceptionally high placebo response rate observed in the HBBI trial is a well-documented challenge in schizophrenia research.[30] This phenomenon can obscure a true drug effect, making it difficult to detect a signal, and likely contributed to the inconclusive nature of that specific Phase II study.
• Patient Heterogeneity: Schizophrenia is now understood to be a heterogeneous syndrome with diverse underlying biologies, not a single monolithic disease. The "one size fits all" approach of testing LY2140023 in a broad population defined only by DSM criteria may have been a critical flaw. This approach could easily mask a genuine therapeutic effect that exists only within a specific, biologically-defined subgroup of patients—a possibility strongly suggested by subsequent post-hoc analyses.

Scientific Legacy: Lessons from Failure and the Future of Glutamatergic Therapies

The discontinuation of pomaglumetad methionil was a significant setback for the field, but its legacy is not one of simple failure. The program provided invaluable lessons that have reshaped the strategy for developing novel therapeutics for psychiatric disorders.

Post-Hoc Analyses: A Signal in the Noise?

Following the program's termination, exploratory analyses of the vast clinical trial database were conducted to determine if any patient subgroups had responded to the treatment. These analyses revealed a potential signal that had been lost in the noise of the larger, heterogeneous population. A key finding was that the 40 mg BID dose of pomaglumetad methionil appeared to show a statistically significant treatment effect versus placebo, but only in a specific sub-population: patients who were "early-in-disease" (defined as an illness duration of three years or less) and who had been previously treated with D2 receptor antagonists.[43]

This finding gave rise to a compelling new hypothesis: that chronic exposure to standard dopaminergic antipsychotics might lead to an epigenetic downregulation of mGluR2 receptors.[43] If true, this would mean that in the chronically ill, heavily pre-treated population that dominated the pivotal trials, the drug's molecular target was no longer sufficiently available to produce a therapeutic effect. The drug may have been effective, but only in a specific patient population that was not prospectively selected for in the registration studies.

The Impact on the Field

The high-profile failure of the pomaglumetad program dealt a "huge blow to the scientific community," creating a chilling effect on investment and research into mGluR2/3 agonists for schizophrenia.[44] It served as a sobering reminder of the immense difficulty in translating promising preclinical concepts into effective medicines for complex CNS disorders.[46] However, it also catalyzed a necessary and critical re-evaluation of the prevailing drug development paradigm.

Lessons Learned and Future Directions

The legacy of LY2140023 is transformative because it highlighted a path forward through its failure.

• The Need for Biomarkers and Patient Stratification: The post-hoc findings were a watershed moment, underscoring the urgent need to move beyond symptom-based diagnostic categories and toward a biologically-based, stratified approach. The failure of LY2140023 became a cornerstone argument for the development of biomarkers (e.g., genetic markers, neuroimaging of glutamate levels) that could identify patient subgroups most likely to respond to a specific mechanism.[43] This inadvertently helped pioneer the concept of precision psychiatry. The subsequent licensing of the drug in 2015 to Denovo Biopharma, a company specializing in using biomarkers to rescue failed drugs for targeted populations, is the direct commercial embodiment of this legacy.[16]
• The Glutamate Hypothesis Endures: The failure of this specific mGluR2/3 agonist did not invalidate the entire glutamate hypothesis of schizophrenia. Instead, it refined it. The field now recognizes that a more nuanced approach is required. Research has shifted to other targets within the glutamate system, such as mGluR2 positive allosteric modulators (PAMs), glycine transporter-1 (GlyT1) inhibitors, and other NMDA receptor modulators, with the crucial lesson that these new agents must be tested in carefully selected patient populations.[5]

Conclusion

LY2140023, pomaglumetad methionil, stands as a landmark case study in modern pharmaceutical development. It was the product of brilliant pharmaceutical chemistry, which successfully solved a critical pharmacokinetic challenge through an innovative prodrug strategy. Its mechanism of action was based on an elegant and compelling scientific hypothesis that promised a paradigm shift in the treatment of schizophrenia by modulating the glutamate system rather than blocking dopamine receptors.

Clinically, the drug delivered on part of its promise, demonstrating a clear and significant advantage over standard antipsychotics by avoiding their most troublesome metabolic and motor side effects. However, this was its only success. The extensive and rigorous late-stage clinical trial program definitively showed that, for the broad population of patients with schizophrenia, pomaglumetad methionil lacked efficacy. It was not superior to placebo and was less effective than existing treatments. Furthermore, its own unique profile of adverse events led to higher rates of treatment discontinuation than a standard-of-care comparator, nullifying its advantages in other areas.

The discontinuation of the program in 2012 was a rational, data-driven decision based on this unfavorable risk/benefit profile. Yet, the scientific legacy of LY2140023 is profound. The post-hoc analyses of its trial data provided some of the most compelling evidence to date for the biological heterogeneity of schizophrenia, suggesting the existence of a "glutamatergic" patient subtype that may respond to this mechanism. In its failure, LY2140023 illuminated the critical need for patient stratification and biomarkers in psychiatric drug development, catalyzing the shift toward a future of precision neuroscience. While the drug itself did not reach the clinic, the lessons learned from its journey continue to guide and inform the search for the next generation of treatments for this devastating illness.

Works cited

1. Glutamate and dopamine in schizophrenia: An update for the 21st century - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/270909628_Glutamate_and_dopamine_in_schizophrenia_An_update_for_the_21st_century
2. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment - PMC, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6953551/
3. (PDF) LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/44696312_LY-2140023_a_prodrug_of_the_group_II_metabotropic_glutamate_receptor_agonist_LY-404039_for_the_potential_treatment_of_schizophrenia
4. Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison - PMC, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3977437/
5. When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia | The British Journal of Psychiatry - Cambridge University Press, accessed September 8, 2025, https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/when-the-drugs-dont-work-the-potential-of-glutamatergic-antipsychotics-in-schizophrenia/B87099274EDC51BD0DFEB51C981F36FF
6. Glutamatergic drugs for schizophrenia - Cochrane, accessed September 8, 2025, https://www.cochrane.org/evidence/CD003730_glutamatergic-drugs-schizophrenia
7. Glutamate-Based Therapeutic Strategies for Schizophrenia: Emerging Approaches Beyond Dopamine - MDPI, accessed September 8, 2025, https://www.mdpi.com/1422-0067/26/9/4331
8. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/22722029/
9. Clinical development of pomaglumetad methionil: A non-dopaminergic treatment for schizophrenia | Request PDF - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/227856579_Clinical_development_of_pomaglumetad_methionil_A_non-dopaminergic_treatment_for_schizophrenia
10. Glutamate and dopamine dysregulation in schizophrenia - a synthesis and selective review, accessed September 8, 2025, https://kclpure.kcl.ac.uk/portal/en/publications/glutamate-and-dopamine-dysregulation-in-schizophrenia--a-synthesis-and-selective-review(1442439a-1335-45ec-a793-0e60405a84f1).html
11. The G Protein-Coupled Glutamate Receptors as Novel Molecular Targets in Schizophrenia Treatment—A Narrative Review - MDPI, accessed September 8, 2025, https://www.mdpi.com/2077-0383/10/7/1475
12. LY, 2140023 monohydrate in the treatment of patients with schizophrenia: Results of 2 clinical trials assessing efficacy in treating acutely ill and those with prominent negative symptoms | Request PDF - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/284890993_LY_2140023_monohydrate_in_the_treatment_of_patients_with_schizophrenia_Results_of_2_clinical_trials_assessing_efficacy_in_treating_acutely_ill_and_those_with_prominent_negative_symptoms
13. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/20571979/
14. LY2140023 | CAS NO.:635318-55-7 - GlpBio, accessed September 8, 2025, https://www.glpbio.com/ly2140023.html
15. LY 2140023 | 635318-55-7 - ChemicalBook, accessed September 8, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB42628059.htm
16. Pomaglumetad methionil (also known as POMA, LY-2140023) - Alzheimer's Drug Discovery Foundation, accessed September 8, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Pomaglumetad.pdf
17. Pomaglumetad methionil anhydrous (LY2140023) | LY404039 Prodrug | MedChemExpress, accessed September 8, 2025, https://www.medchemexpress.com/ly2140023.html
18. Pomaglumetad Methionil | C12H20N2O8S2 | CID 56842185 - PubChem, accessed September 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/56842185
19. Pomaglumetad methionil hydrochloride Datasheet DC Chemicals, accessed September 8, 2025, https://www.dcchemicals.com/product_show-Pomaglumetad_methionil_hydrochloride.html?datasheet=datasheet
20. Pomaglumetad methionil hydrochloride | CAS NO.:635318-26-2 | GlpBio, accessed September 8, 2025, https://www.glpbio.com/pomaglumetad-methionil-hydrochloride.html
21. POMAGLUMETAD - Inxight Drugs, accessed September 8, 2025, https://drugs.ncats.io/substance/531QUG7P9E
22. Pomaglumetad - Wikipedia, accessed September 8, 2025, https://en.wikipedia.org/wiki/Pomaglumetad
23. Discovery of LY2140023, a peptide prodrug of the mGlu2/3 receptor agonist LY404039 | Request PDF - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/315488942_Discovery_of_LY2140023_a_peptide_prodrug_of_the_mGlu23_receptor_agonist_LY404039
24. LY2140023 Completed Phase 1 Trials for Healthy Volunteers (HV) Treatment - DrugBank, accessed September 8, 2025, https://go.drugbank.com/drugs/DB05096/clinical_trials?conditions=DBCOND0114743&phase=1&purpose=treatment&status=completed
25. LY2140023 Completed Phase 1 Trials for Schizophrenia Basic Science | DrugBank Online, accessed September 8, 2025, https://go.drugbank.com/drugs/DB05096/clinical_trials?conditions=DBCOND0018504&phase=1&purpose=basic_science&status=completed
26. LY2140023 Completed Phase 1 Trials for Clinical High Risk for Psychosis Treatment, accessed September 8, 2025, https://go.drugbank.com/drugs/DB05096/clinical_trials?conditions=DBCOND0061198&phase=1&purpose=treatment&status=completed
27. LY2140023 Terminated Phase 1 Trials for Post Traumatic Stress Disorder (PTSD) Treatment, accessed September 8, 2025, https://go.drugbank.com/drugs/DB05096/clinical_trials?conditions=DBCOND0038601&phase=1&purpose=treatment&status=terminated
28. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds | Eli Lilly and Company, accessed September 8, 2025, https://investor.lilly.com/news-releases/news-release-details/investigational-agent-targeting-metabotropic-glutamate-23
29. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohyd, accessed September 8, 2025, https://d-nb.info/1085673650/34
30. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research, accessed September 8, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-announces-inconclusive-phase-ii-study-results-mglu23
31. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3666887/
32. A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/25539791/
33. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study, accessed September 8, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-announces-pomaglumetad-methionil-did-not-meet-primary
34. Med Check | Psychiatric News - Psychiatry Online, accessed September 8, 2025, https://www.psychiatryonline.org/doi/10.1176/pn.47.19.psychnews_47_19_23-a
35. Lilly Stops Phase III Development of Pomaglumetad Methionil For ..., accessed September 8, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-stops-phase-iii-development-pomaglumetad-methionil
36. Strike three: Bad data bury Eli Lilly's late-stage schizophrenia drug | Fierce Biotech, accessed September 8, 2025, https://www.fiercebiotech.com/r-d/strike-three-bad-data-bury-eli-lilly-s-late-stage-schizophrenia-drug
37. Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo | Request PDF - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/256610046_Pomaglumetad_methionil_No_significant_difference_as_an_adjunctive_treatment_for_patients_with_prominent_negative_symptoms_of_schizophrenia_compared_to_placebo
38. (PDF) Pomaglumetad Methionil (LY2140023 Monohydrate) and ..., accessed September 8, 2025, https://www.researchgate.net/publication/261923516_Pomaglumetad_Methionil_LY2140023_Monohydrate_and_Aripiprazole_in_Patients_with_Schizophrenia_A_Phase_3_Multicenter_Double-Blind_Comparison
39. Pomaglumetad Methionil (LY2140023 Monohydrate) and ... - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/24772351/
40. LY2140023 Completed Phase 3 Trials for Schizophrenia Treatment | DrugBank Online, accessed September 8, 2025, https://go.drugbank.com/drugs/DB05096/clinical_trials?conditions=DBCOND0018504&phase=3&purpose=treatment&status=completed
41. A Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of a Metabotropic Glutamate 2/3 Receptor Agonist Using an Electronic Patient-Reported Outcome Device in Patients With Schizophrenia - PubMed Central, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4165473/
42. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/23694720/
43. Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia | Request PDF - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/273834069_Exploratory_Analysis_for_a_Targeted_Patient_Population_Responsive_to_the_Metabotropic_Glutamate_23_Receptor_Agonist_Pomaglumetad_Methionil_in_Schizophrenia
44. Perspectives on the Mglur2/3 Agonists As a Therapeutic Target for Schizophrenia: Still Promising or a Dead End? - AMiner, accessed September 8, 2025, https://aminer.org/pub/55a6bb2965ce054aad7324ae
45. Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: still promising or a dead end? - PMC - PubMed Central, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4426221/
46. Boehringer's phase 3 schizophrenia program misses primary goal - Fierce Biotech, accessed September 8, 2025, https://www.fiercebiotech.com/biotech/boehringers-phase-3-schizophrenia-program-misses-primary-goal
47. Glutamate-Based Therapeutic Strategies for Schizophrenia: Emerging Approaches Beyond Dopamine - PMC - PubMed Central, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12072206/
48. Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo | Semantic Scholar, accessed September 8, 2025, https://www.semanticscholar.org/paper/Pomaglumetad-methionil%3A-No-significant-difference-Stauffer-Millen/2de4b8975d7c3e53cc526c89fabd8f0cc9bd5b20